Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

334P - Prognostic factors for early recurrence after resection of pancreatic cancer: A systematic review and meta-analysis

Date

27 Jun 2024

Session

Poster Display session

Presenters

Carl Leonhardt

Citation

Annals of Oncology (2024) 35 (suppl_1): S119-S161. 10.1016/annonc/annonc1481

Authors

C. Leonhardt1, C. Gustorff1, U. Klaiber1, S. Leblanc1, T. Stamm2, C. Verbeke3, G. Prager4, O. Strobel1

Author affiliations

  • 1 MedUni Wien - Medical University of Vienna, Vienna/AT
  • 2 Medical University of Vienna, Vienna/AT
  • 3 Oslo University Hospital Rikshospitalet, Oslo/NO
  • 4 Universitätskliniken der MedUni Wien - AKH Wien, 1090 - Vienna/AT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 334P

Background

Over half of pancreatic ductal adenocarcinomas (PDAC) recur within 12 months after curative intent resection. The aim of this systematic review and meta-analysis was to identify all reported prognostic factors for early recurrence in resected PDAC.

Methods

Following a systematic literature search, meta-analysis was conducted using a random-effects model. Separate analyses were performed for adjusted vs unadjusted effect estimates as well as reported odds ratios (OR) and hazard ratios (HR). Risk of bias was assessed using the QUIPS tool and evidence rated according to GRADE recommendations.

Results

After screening 2,903 abstracts, 65 studies were included. Twenty-eight (43.1%) studies defined early recurrence as evidence of recurrence within 6 months, while 34 (52.3%) defined it as evidence of recurrence within 12 months after surgery. Other definitions were uncommon. Analysis of unadjusted OR and HR revealed 41 and 5 prognostic factors for early recurrence within 6 months, respectively. When exclusively considering adjusted data, 25 and 10 prognostic factors were identified based on OR and HR, respectively. Using a 12-month definition, 38 (OR) and 15 (HR) prognostic factors were identified from unadjusted data and 38 (OR) and 30 (HR) prognostic factors from adjusted data, respectively. Based on frequency counts of adjusted data, preoperative CA19-9, N status, adjuvant therapy, grading, and tumor size based on imaging were identified as key prognostic factors for early recurrence.

Conclusions

Reported prognostic factors of early recurrence vary considerably. Identified key prognostic factors could aid in the development of a risk stratification framework for early recurrence. However, prospective validation is necessary.

Legal entity responsible for the study

Carl Leonhardt.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.